Why the study?
Does intravenous nesiritide improve hemodynamics and symptoms compared to dobutamine or nitroglycerin in patients with decompensated heart failure?
Population
Patients with decompensated heart failure (almost 1,000 patients across numerous clinical investigations)
Comparison
Intravenous nesiritide vs Dobutamine or intravenous nitroglycerin
Design
Review
Authors
Loading...
Should not yet alter vasodilator choice in acute HF; leaves open need for head-to-head RCTs including dobutamine.
Does intravenous nesiritide improve hemodynamics and symptoms compared to dobutamine or nitroglycerin in patients with decompensated heart failure?
Nesiritide is a promising treatment for decompensated heart failure that improves hemodynamics and symptoms more effectively than nitroglycerin with a favorable safety profile.
Burger et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: